Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

21
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
21
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

19
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Macroeconomic impact of Ebola outbreaks in Sub-Saharan Africa and potential mitigation of GDP loss with prophylactic Ebola vaccination programs.

PloS one·2023
Same author

Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study.

Vaccine·2022
Same author

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.

Oncology and therapy·2021
Same author

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma.

HemaSphere·2020
Same author

Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany.

Future oncology (London, England)·2020
Same author

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.

Leukemia & lymphoma·2018

Related Experiment Video

Updated: Apr 25, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

29.8K

Evaluating disease-modifying agents: a simulation framework for Alzheimer's disease.

Shien Guo1, Denis Getsios, Nikhil Revankar

  • 1Evidera, 430 Bedford Street, Suite 300, Lexington Office Park, Lexington, MA, 02420, USA, shien.guo@evidera.com.

Pharmacoeconomics
|August 16, 2014
PubMed
Summary

This study developed an updated economic model for Alzheimer's disease (AD) to evaluate disease-modifying agents (DMAs). The flexible model accurately predicts disease progression and assesses the economic impact of DMAs.

More Related Videos

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

10.1K
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

7.6K

Related Experiment Videos

Last Updated: Apr 25, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

29.8K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

10.1K
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

7.6K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Biostatistics

Background:

  • Existing Alzheimer's disease (AD) models require updates to incorporate potential disease-modifying agents (DMAs).
  • There is a need for advanced simulation frameworks to evaluate DMAs at an individual level, considering multiple disease dimensions.

Purpose of the Study:

  • To develop a flexible simulation model for the economic evaluation of DMAs in Alzheimer's disease.
  • To enhance existing models by incorporating patient dependence as a key measure of disease severity.

Main Methods:

  • The study adapted a discrete event simulation model, incorporating patient dependence alongside cognition, behavior, and function.
  • The model was enhanced for flexibility to assess long-term DMA effectiveness and survival impacts.
  • Validation involved comparing model predictions to Phase III clinical trial data for bapineuzumab.

Main Results:

  • The updated model demonstrated close prediction of mean disease severity changes over 18 months.
  • Simulations showed the model's capability to credibly assess uncertainties in DMA long-term effectiveness and survival benefits.
  • Varying assumptions significantly impacted the estimated value of DMAs.

Conclusions:

  • The enhanced economic model exhibits strong predictive capabilities for Alzheimer's disease progression.
  • Further validation against longer-term outcomes is recommended.
  • Model flexibility is crucial for assessing the impact of uncertainties on the value of disease-modifying agents.